Ascentage Pharma Group International (HKSE:06855) Debt-to-Equity : 29.72 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International Debt-to-Equity?

Ascentage Pharma Group International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$674.2 Mil. Ascentage Pharma Group International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,289.8 Mil. Ascentage Pharma Group International's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$66.1 Mil. Ascentage Pharma Group International's debt to equity for the quarter that ended in Dec. 2023 was 29.72.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Ascentage Pharma Group International's Debt-to-Equity or its related term are showing as below:

HKSE:06855' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.06 Med: 0.37 Max: 29.72
Current: 29.72

During the past 8 years, the highest Debt-to-Equity Ratio of Ascentage Pharma Group International was 29.72. The lowest was -0.06. And the median was 0.37.

HKSE:06855's Debt-to-Equity is ranked worse than
99.62% of 1060 companies
in the Biotechnology industry
Industry Median: 0.14 vs HKSE:06855: 29.72

Ascentage Pharma Group International Debt-to-Equity Historical Data

The historical data trend for Ascentage Pharma Group International's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International Debt-to-Equity Chart

Ascentage Pharma Group International Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.11

0.63

0.88

4.39

29.72

Ascentage Pharma Group International Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial									0.88	1.78	4.39	2.84	29.72

Competitive Comparison of Ascentage Pharma Group International's Debt-to-Equity

For the Biotechnology subindustry, Ascentage Pharma Group International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascentage Pharma Group International's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's Debt-to-Equity falls into.

Ascentage Pharma Group International Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Ascentage Pharma Group International's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(674.21	+	1289.774)	/	66.083
	=	29.72

Ascentage Pharma Group International's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(674.21	+	1289.774)	/	66.083
	=	29.72

Ascentage Pharma Group International (HKSE:06855) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Ascentage Pharma Group International Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascentage Pharma Group International (HKSE:06855) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (HKSE:06855) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ASPHF:USA 36X:Germany

Address

68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000

Website

https://www.ascentagepharma.com

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company's geographical segments include the United States and Mainland China.

Executives

Ascentage Limited
Gao Sharon Xia
Guo Edward Ming
Healthquest Pharma Limited
Li Ju-yun
Wang Shaomeng
Yang Dajun
Zhai Yifan
South Dakota Trust Company Llc	2301 Trustee
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Tian Yuan	2201 Interest of corporation controlled by you
Zhao Li	2202 Interest of your spouse
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin You Xian He Huo	2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi You Xian Gong Si	2101 Beneficial owner
Guo Tou Chuang Xin Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you

Ascentage Pharma Group International (HKSE:06855) Headlines

No Headlines